PMID- 28893478
OWN - NLM
STAT- MEDLINE
DCOM- 20180314
LR  - 20181202
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 35
IP  - 42
DP  - 2017 Oct 9
TI  - Pain caused by measles, mumps, and rubella vaccines: A systematic literature 
      review.
PG  - 5551-5558
LID - S0264-410X(17)31166-0 [pii]
LID - 10.1016/j.vaccine.2017.08.068 [doi]
AB  - PURPOSE: The risk of post-vaccination adverse events (AEs) is a primary public 
      health concern. Among the AEs, pain is a significant source of anxiety for both 
      children and their parents. This review describes and assesses the intensity of 
      pain experienced by children post-vaccination with widely used 
      Measles-Mumps-Rubella (MMR) vaccines. METHODS: A systematic literature search was 
      conducted in Pubmed, Embase and Cochrane to identify publications describing 
      immediate pain at injection site (primary objective) or pain within days 
      (secondary objective) after 2 specific MMR vaccines. Immediate pain ('acute pain' 
      according to the Brighton Collaboration case definition) was defined as pain 
      occurring at the time or within 5min of injection. RESULTS: Four studies, which 
      compared the intensity of immediate injection site pain experienced by children 
      after MMR vaccination, were identified. Various pain assessment tools and methods 
      were used to quantify the intensity of pain, including the median difference in 
      Visual Analog Scale scores between vaccine groups. All four studies showed 
      significantly less immediate pain caused by Priorix (GSK Vaccines) compared with 
      M-M-R II (Merck & Co., Inc.). CONCLUSIONS: To our knowledge, this review 
      summarizes for the first time the available scientific evidence on the intensity 
      of pain following different MMR vaccines. It highlights that MMR vaccines can 
      differ in terms of immediate pain. Further research may be needed to better 
      understand the underlying reason for this observation. In this context, it is 
      very important to understand which physicochemical properties are most relevant 
      for the immediate pain profile of a vaccine to thereby support the development of 
      vaccines with the best possible immediate pain profile.
CI  - Copyright (c) 2017. Published by Elsevier Ltd.
FAU - Willame, Corinne
AU  - Willame C
AD  - Business & Decision Life Sciences, Rue Saint Lambert 141, 1200 Brussels, 
      Belgium(1). Electronic address: corinne.x.willame@gsk.com.
FAU - Henry, Ouzama
AU  - Henry O
AD  - GSK, 2301 Renaissance Blvd., King of Prussia, Philadelphia, PA 19406-2772, USA. 
      Electronic address: ouzama.n.henry@gsk.com.
FAU - Lin, Lan
AU  - Lin L
AD  - GSK, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: 
      lan-lin.d.cresens@gsk.com.
FAU - Vetter, Volker
AU  - Vetter V
AD  - GSK, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: 
      volker.v.vetter@gsk.com.
FAU - Baril, Laurence
AU  - Baril L
AD  - GSK, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: 
      laurencebaril1@gmail.com.
FAU - Praet, Nicolas
AU  - Praet N
AD  - GSK, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: 
      nicolas.x.praet@gsk.com.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Measles-Mumps-Rubella Vaccine)
RN  - 0 (Vaccines, Combined)
SB  - IM
MH  - Humans
MH  - Measles-Mumps-Rubella Vaccine/*adverse effects
MH  - Pain/*chemically induced
MH  - Vaccination/*adverse effects
MH  - Vaccines, Combined/*adverse effects
OTO - NOTNLM
OT  - Immediate pain
OT  - Literature review
OT  - Measles-mumps-rubella vaccination
EDAT- 2017/09/13 06:00
MHDA- 2018/03/15 06:00
CRDT- 2017/09/13 06:00
PHST- 2016/12/06 00:00 [received]
PHST- 2017/08/04 00:00 [revised]
PHST- 2017/08/24 00:00 [accepted]
PHST- 2017/09/13 06:00 [pubmed]
PHST- 2018/03/15 06:00 [medline]
PHST- 2017/09/13 06:00 [entrez]
AID - S0264-410X(17)31166-0 [pii]
AID - 10.1016/j.vaccine.2017.08.068 [doi]
PST - ppublish
SO  - Vaccine. 2017 Oct 9;35(42):5551-5558. doi: 10.1016/j.vaccine.2017.08.068.